Cargando…

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Sorafenib is still the only systemic drug approved for the treatment of advanced hepatocellular carcinoma (HCC). In recent years, several investigational agents mainly targeting angiogenesis failed in late-phase clinical development due to either toxicity or lack of benefit. Recently, data of the RE...

Descripción completa

Detalles Bibliográficos
Autores principales: Trojan, Jörg, Waidmann, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036543/
https://www.ncbi.nlm.nih.gov/pubmed/27703962
http://dx.doi.org/10.2147/JHC.S112537